Dermatology focuses on the health of the skin, hair, and nails. Learn about the diagnosis and treatment of acne, eczema, skin cancer, and cosmetic procedures.
Send us all your questions or requests, and our expert team will assist you.
The Diagnosis and Evaluation process for basal cell carcinoma (BCC) is a critical step in ensuring effective treatment and optimal outcomes for patients worldwide. At Liv Hospital, our multidisciplinary dermatology team follows a systematic approach that begins with a thorough clinical examination and extends to advanced imaging, histopathological analysis, and personalized risk assessment. According to the World Health Organization, BCC accounts for nearly 80% of all skin cancers, making early detection essential.
This page is designed for international patients seeking clear, detailed information about how BCC is identified and staged before therapy. We will walk you through each stage of the diagnostic pathway, explain the technologies we employ, and describe how our experts collaborate to create a tailored treatment plan. Understanding the full scope of diagnosis and evaluation empowers patients to make informed decisions and feel confident in the care they receive at Liv Hospital.
Whether you are preparing for your first consultation or reviewing follow‑up results, the insights provided here will help you navigate the journey from suspicion to a definitive diagnosis, and ultimately, to successful management of basal cell carcinoma.
Recognizing the early signs of basal cell carcinoma is the cornerstone of accurate diagnosis and evaluation. Patients typically present with lesions that may appear as pearly nodules, ulcerated patches, or scar‑like growths, often on sun‑exposed areas such as the face, neck, and arms. A detailed medical history, including prior skin cancers, UV exposure, and immunosuppression, guides the dermatologist in estimating risk.
During the initial assessment, the clinician performs:
These findings are recorded in a standardized skin cancer registry, which facilitates longitudinal monitoring. In cases where the lesion is ambiguous, the dermatologist may proceed directly to imaging or biopsy to refine the diagnosis and evaluation process.
While many basal cell carcinomas can be diagnosed clinically, imaging plays a pivotal role when lesions are large, recurrent, or located in anatomically complex regions. Advanced imaging provides precise information about tumor depth, perineural involvement, and proximity to critical structures, all of which influence treatment planning.
Key imaging modalities include:
Our radiology department integrates these tools seamlessly into the diagnosis and evaluation workflow, ensuring that each patient receives a comprehensive anatomical map of their disease.
When visual and imaging assessments suggest malignancy, a tissue sample is essential for definitive diagnosis and evaluation. The choice of biopsy technique depends on lesion size, location, and suspected depth.
Common biopsy methods include:
All specimens are processed in our state‑of‑the‑art pathology lab, where board‑certified dermatopathologists examine the tissue under light microscopy and may employ immunohistochemical stains to differentiate BCC from other skin neoplasms. The pathology report provides critical details such as histologic subtype (e.g., nodular, infiltrative, morpheaform), margin status, and perineural invasion, which are integral components of the overall diagnosis and evaluation strategy.
Accurate staging translates the findings from clinical, imaging, and pathological assessments into a clear risk profile. While basal cell carcinoma rarely metastasizes, certain features—such as size >2 cm, aggressive histologic subtypes, and deep tissue involvement—warrant a more intensive treatment approach.
The American Joint Committee on Cancer (AJCC) 8th edition provides a staging system that categorizes BCC based on:
Our multidisciplinary team incorporates these criteria into a personalized risk matrix, which guides decisions regarding surgical margins, the need for adjunctive radiotherapy, or consideration of targeted systemic therapies. By aligning the comprehensive diagnosis and evaluation data with established staging guidelines, we ensure that each patient receives care proportional to the aggressiveness of their disease.
Basal cell carcinoma management benefits from a collaborative approach that brings together dermatologists, surgical oncologists, radiologists, pathologists, and reconstructive specialists. After completing the diagnosis and evaluation phase, the case is reviewed at a tumor board meeting where all relevant data are discussed.
Key elements of the treatment planning session include:
For high‑risk or recurrent lesions, our team may recommend a combination of modalities, such as surgical removal followed by adjuvant radiotherapy. The comprehensive diagnosis and evaluation data serve as the foundation for these nuanced decisions, ensuring that each plan is evidence‑based and patient‑centered.
Even after successful treatment, vigilant follow‑up is essential because basal cell carcinoma can recur, especially in high‑risk patients. The follow‑up protocol is tailored based on the initial diagnosis and evaluation findings and the chosen treatment modality.
Typical surveillance includes:
Our electronic medical record system flags patients for timely appointments and automatically generates reminders for both patients and clinicians. By maintaining a rigorous follow‑up schedule, we close the loop on the diagnosis and evaluation continuum, catching any new or recurrent lesions early and preserving skin health.
Liv Hospital combines JCI‑accredited standards with a dedicated international patient program, offering seamless coordination from initial consultation through post‑treatment follow‑up. Our dermatology specialists are experienced in the latest diagnostic technologies and evidence‑based management of basal cell carcinoma. International patients benefit from personalized language support, travel assistance, and comfortable accommodation options, ensuring a stress‑free experience while receiving world‑class care.
Ready to schedule your comprehensive basal cell carcinoma assessment? Contact Liv Hospital today to arrange a virtual consultation and discover how our expert team can guide you through every step of diagnosis and evaluation.
Liv Hospital Ulus
Asst. Prof. MD. Ayşe Deniz Akkaya
Dermatology
Liv Hospital Ulus
Asst. Prof. MD. Nazlı Caf
Dermatology
Liv Hospital Ulus
Prof. MD. İlteriş Oğuz
Dermatology
Liv Hospital Ulus
Spec. MD. Ömer Gezdur
Dermatology
Liv Hospital Vadistanbul
Assoc. Prof. MD. Ece Altun
Dermatology
Liv Hospital Vadistanbul
Prof. MD. Sevilay Oğuz Kılıç
Dermatology
Liv Hospital Vadistanbul
Spec. MD. Marziyeh Javadpour
Dermatology
Liv Hospital Vadistanbul
Spec. MD. Meryem Ayşit
Dermatology
Liv Hospital Bahçeşehir
Assoc. Prof. MD. Nadir Göksügür
Dermatology
Liv Hospital Bahçeşehir
Spec. MD. Esengül Kaya
Dermatology
Liv Hospital Bahçeşehir
Spec. MD. Vedat Ertunç
Dermatology
Liv Hospital Bahçeşehir
Spec. MD. Özlem İpek
Dermatology
Liv Hospital Topkapı
Spec. MD. Betül Kızılkan
Dermatology
Liv Hospital Topkapı
Spec. MD. Gizem Gökçedağ Ünsal
Dermatology
Liv Hospital Ankara
Asst. Prof. MD. Caner Demircan
Dermatology
Liv Hospital Ankara
Spec. MD. Aylin Gözübüyükoğulları
Dermatology
Liv Hospital Ankara
Spec. MD. Elçin Akdaş
Dermatology
Liv Hospital Ankara
Spec. MD. Vahid Ahmadi
Dermatology
Liv Hospital Gaziantep
Spec. MD. Hatice Kübra Çakı
Dermatology
Liv Hospital Samsun
Asst. Prof. MD. Gül Şekerlisoy Tatar
Dermatology
Liv Hospital Samsun
Spec. MD. Ayşe İdil Baş
Dermatology
Liv Bona Dea Hospital Bakü
Spec. MD. İRFAN QEHREMANOV
Dermatology
Asst. Prof. MD. A. Deniz Akkaya
Dermatology
MD. Gül Şekerlisoy Tatar
Dermatology
Send us all your questions or requests, and our expert team will assist you.
Basal cell carcinoma typically presents on areas such as the face, neck, and arms that have received significant UV exposure. Lesions may look like translucent, pearly papules with telangiectasia, or they can become ulcerated and crusted over time. Some patients notice a raised, flesh‑colored nodule that bleeds or becomes tender. Recognizing these patterns, along with a personal history of skin cancer or immunosuppression, helps clinicians suspect BCC early and proceed with diagnostic steps.
Imaging is reserved for larger, recurrent, or anatomically complex BCCs. High‑resolution ultrasound provides real‑time measurement of lesion thickness and vascularity. Optical coherence tomography (OCT) offers microscopic visualization of superficial layers without radiation. MRI excels at evaluating deep tissue involvement and perineural spread, while CT is useful for assessing bone invasion in facial lesions. Each modality has specific advantages and limitations, and Liv Hospital selects the appropriate tool based on lesion characteristics.
When clinical or imaging findings suggest malignancy, a tissue sample is required. A punch biopsy removes a cylindrical core and is ideal for small to medium lesions. Excisional biopsy removes the entire lesion with margins, suitable for well‑defined tumors. Incisional biopsy samples part of a larger lesion, preserving tissue for further analysis. Shave biopsy takes a superficial slice, best for raised, superficial BCCs. All specimens are processed by board‑certified dermatopathologists, who assess histologic subtype, margins, and high‑risk features.
The AJCC 8th edition classifies BCC from T1 to T4 based on size (e.g., ≤2 cm = T1) and depth of invasion into subcutaneous tissue, muscle, or bone. High‑risk characteristics—large size, aggressive histologic subtypes (infiltrative, morpheaform), ulceration, perineural involvement, or recurrence—upstage the tumor and may prompt more aggressive treatment. Liv Hospital integrates these criteria into a personalized risk matrix that guides surgical margins, the need for adjuvant radiotherapy, or systemic therapy.
After diagnosis, the patient’s data—including clinical photos, dermoscopic images, imaging studies, and pathology reports—are presented at a multidisciplinary tumor board. The team evaluates lesion location, size, histology, patient comorbidities, cosmetic concerns, and preferences. Together they decide on the optimal therapy, which may be Mohs micrographic surgery, standard excision, radiotherapy, or targeted Hedgehog pathway inhibitors. For high‑risk or recurrent tumors, combined modalities (e.g., surgery plus adjuvant radiotherapy) are often recommended.
BlogDermatologyApr 10, 2026Did you know over 10 million people in the U.S. have allergies bad enough for allergy immunotherapy? This t...
BlogDermatologyApr 10, 2026Nearly 1 in 5 people who get a chemical peel face skin irritation or reaction. This makes taking good care ...
BlogDermatologyApr 10, 2026More than 100 million people in the United States deal with allergies every year. Finding good allergy reli...
BlogDermatologyApr 10, 2026A dermatopathologist is a doctor who specializes in skin diseases. They look at tissue samples under a micr...
BlogDermatologyApr 09, 2026We focus on aesthetic dermatology, which aims to improve beauty and health. An aesthetic dermatologist is k...
BlogDermatologyApr 09, 2026Discover the vital role of melanocytes in skin health and protection. Learn about their anatomy, function, ...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 26 75